Washington, D.C. (November 16, 2010) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Wes Metheny issued the following statement today regarding the Tufts Center for the Study of Drug Development Impact Report on personalized medicine research:
“Today’s report from the Tufts Center for the Study of Drug Development demonstrates the commitment of America’s biopharmaceutical research companies to personalized medicine research. This research has the potential to open new doors in the pursuit of medical progress, and with 94 percent of surveyed companies currently investing in the field, and a full 100 percent using personalized medicine approaches such as biomarkers to evaluate compounds in the discovery process, the promise for America’s patients is stronger than ever.
“Also, the research appears to be yielding positive results, with companies reporting that up to half of their current pipelines involve personalized medicines.
“Unsurprisingly, cancer leads the field of personalized medicine research, both in terms of already-marketed technologies and the pipeline. However, personalized medicine research is not limited to oncology, but rather encompasses many therapeutic areas: it is integrated in research on cardiovascular diseases, central nervous system conditions, and immunology, for example. And, according to the Tufts report, personalized medicine research is now expanding into metabolic and respiratory therapies as well as virology. What’s more, much of this work is used solely to improve a company’s understanding of their research, rather than for regulatory approval.
“Importantly, the report makes clear that personalized medicine represents a dramatically new field in biopharmaceutical research. It requires significant investment beyond the traditional R&D process – itself costly and lengthy – such as technologies associated with target validation, early toxicology markers, and micro-sequencing. The report also explains that the changing R&D paradigm presented by personalized medicine research can also mean partnerships beyond the usual collaborations associated with biopharmaceutical research, raising issues involving intellectual property rights – a major incentive for continued innovation.
“Between 2006 and 2010, company investment in personalized medicine research increased by a mean of 75 percent, and Tufts expects an additional increase of 53 percent through 2015.
“America’s biopharmaceutical research companies are ‘pushing strongly ahead’ in the world of personalized medicine research, the report emphasizes. The commitment to America’s patients remains strong, fostering investment in innovation that may lead to tomorrow’s life-saving new medicines.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $45.8 billion in 2009 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.3 billion in 2009.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.
PhRMA Internet Address: www.phrma.org
For information on stories of hope and survival, visit: http://sharingmiracles.com/
For information on how innovative medicines save lives, visit: www.innovation.org
For information on the Partnership for Prescription Assistance, visit: www.pparx.org
For more information on public health emergencies, visit: www.rxresponse.org